GSK has delivered a solid multi year share price run, helped by fresh moves in oncology and vaccines, and that raises a ...

Since I last checked on the British pharmaceuticals' stock GSK (GSK) in December last year, its price has risen by 12%. Interestingly, this is despite the stock having lost 11% of its value since the ...

GSK (LSE:GSK) agreed to acquire Chimagen's trispecific T cell-engager candidate for multiple myeloma, expanding its blood cancer research portfolio. The drug asset is described by the parties as a ...

The last time I wrote about GSK plc (GSK) for Seeking Alpha, it was late September, and I was covering the news that its CEO since 2017, Emma Walmsley, was stepping away from the role to be replaced ...